Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo

Relationship Between Intraocular Pressure Fluctuation and Retinal Ganglion Cell Function in Eyes Receiving Latanoprost 0.005% Versus Placebo

The purpose of this investigation is to evaluate the relationship between IOP fluctuation, RGC dysfunction, and optic nerve and retinal nerve fiber layer (RNFL) thickness changes in patients with glaucoma and ocular hypertension receiving latanoprost 0.005% versus placebo.

Study Overview

• Status: Completed
• Conditions: Glaucoma
• Intervention / Treatment: Drug: Placebo; Drug: latanoprost 0.005%

Detailed Description

It has been hypothesized that intraocular (IOP) variability is an independent risk factor for the progression of glaucoma. IOP variability includes 24 hour IOP fluctuation during the waking period (diurnal fluctuation) and sleep period (nocturnal fluctuation) as well as longitudinal IOP variability measured in the diurnal period over the course of multiple office visits.

Latanoprost has been clinically used to lower eye pressure in glaucoma and ocular hypertension for almost 10 years. Latanoprost 0.005% has been demonstrated to provide superior ocular hypotensive efficacy compared with timolol 0.5% in pivotal phase 3 clinical trials (Alm et al. 1995; Camras 1996).

The Pattern Electroretinogram (PERG) is a non-invasive technology that objectively measures the retinal ganglion cell (RGC) function (Porciatti and Ventura 2004). A recent study has demonstrated that the RGC function can be improved following IOP reduction in glaucomatous eyes with early visual field defects (Ventura and Porciatti 2005).

The purpose of this investigation is to evaluate the relationship between IOP fluctuation, RGC dysfunction, and optic nerve and retinal nerve fiber layer (RNFL) thickness changes in patients with glaucoma and ocular hypertension receiving latanoprost 0.005% versus placebo.

• Study Type: Observational
• Enrollment (Actual): 82

Contacts and Locations

Study Locations

• United States
  • Florida
    • Palm Beach Gardens, Florida, United States, 33418
      • University of Miami Bascom Palmer Eye Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients with primary open angle glaucoma or ocular hypertension from the Glaucoma Clinic at Bascom Palmer Eye Institute- Palm Beach Office.

Description

Inclusion Criteria:

Inclusion Criteria - OHT:

• Ocular hypertension defined as an IOP ≥ 24 mm Hg and ≤ 32 mm Hg in one eye and IOP ≥ 22 mm Hg and ≤ 32 mm Hg in the fellow eye
• Normal optic disc
• Normal visual field defined as follows:
• Mean Deviation (MD) or Pattern Standard Deviation (PSD) of p>5%
• Normal Glaucoma Hemifield Test (GHT)
• Reliable visual field exam (less than 33% false positives or false negatives, and less than 20% fixation losses)

Inclusion Criteria - POAG:

• Glaucomatous visual field loss defined as a CPSD (p < 0.05), or GHT (p < 1%) outside normal limits with consistent with ONH or NFL defect
• Early visual field loss defined as MD ≤ -6.0 dB
• Untreated IOP ≤ 32 mmHg
• ONH or NFL defect defined as either inter-eye CDR asymmetry > 0.2, rim thinning or notching, or NFL bundle defect visible on slitlamp biomicroscopy and stereo color fundus photography

Exclusion Criteria:

Exclusion Criteria - OHT:

• Best-corrected visual acuity less than 20/40 either eye
• Abnormal or unreliable VF
• Untreated IOP > 32 mmHg
• Age < 18 or >85 years
• Refractive error of > +3.00 D or < -7.00 D
• Previous intraocular surgery except for uncomplicated cataract extraction with posterior chamber intraocular lens implantation
• Need for chronic ocular or systemic corticosteroid use
• Narrow/closed angle (gonioscopy must show 75% or more of the angle to be Grade 2 or more by Shaffer's grading system)
• Diabetic retinopathy
• Other diseases that may cause VF loss or optic disc abnormalities
• Life-threatening or debilitating illness making it unlikely patient could successfully complete the study
• Inability to clinically view or photograph the optic discs due to media opacity or poorly dilating pupil
• Refusal of informed consent or of commitment to the full length of the study
• Contraindication to latanoprost or placebo vehicle

Exclusion criteria - POAG:

• Best-corrected visual acuity less than 20/40
• Untreated IOP > 32 mmHg
• Age < 18 or >85 years
• Refractive error of > +3.00 D or < -7.00 D
• Previous intraocular surgery except for uncomplicated cataract extraction with posterior chamber intraocular lens implantation
• Diabetic retinopathy
• Other diseases that may cause VF loss or optic disc abnormalities
• Inability to clinically view or photograph the optic discs due to media opacity or poorly dilating pupil
• Inability to perform reliably on automated VF testing
• Life-threatening or debilitating illness making it unlikely patient could successfully complete the study.
• Refusal of informed consent or of commitment to the full length of the study
• Contraindication to latanoprost or placebo vehicle

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
primary open angle glaucoma; Patients with glaucomatous optic neuropathy defined as narrowing of the neuroretinal rim, notching, excavation, or RNFL defect; and repeatable standard automated perimetry abnormality defined as a glaucoma hemifield test (GHT) "outside normal limits" or pattern standard deviation (PSD) outside 95% normal limits were included.	Drug: Placebo; Placebo comparator; Other Names: Inactive tear drops; Drug: latanoprost 0.005%; Active comparator; Other Names: Xalatan
Ocular Hypertensive group; Ocular hypertension defined as an intraocular pressure ≥ 24 mm Hg and ≤ 32 mm Hg in one eye and IOP ≥ 22 mm Hg and ≤ 32 mm Hg in the fellow eye, with normal optic disc, normal visual field defined as follows mean Deviation (MD) or Pattern Standard Deviation (PSD) of p>5%, normal Glaucoma Hemifield Test (GHT) and reliable visual field exam	Drug: Placebo; Placebo comparator; Other Names: Inactive tear drops; Drug: latanoprost 0.005%; Active comparator; Other Names: Xalatan

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evidence of impact of intraocular (IOP) reduction on retinal ganglion cell (RGC) function	RGC function is evaluated by pattern electroretinogram optimized for glaucoma (PERGLA)	8 weeks

Collaborators and Investigators

• Sponsor: University of Miami
• Collaborators: Pfizer
• Investigators: Principal Investigator: David S Greenfield, MD, University of Miami Bascom Palmer Eye Institute

Study record dates

Study Major Dates

• Study Start: February 1, 2006
• Primary Completion (Actual): December 1, 2009
• Study Completion (Actual): December 1, 2009

Study Registration Dates

• First Submitted: January 4, 2010
• First Submitted That Met QC Criteria: January 4, 2010
• First Posted (Estimate): January 5, 2010

Study Record Updates

• Last Update Posted (Estimate): March 28, 2014
• Last Update Submitted That Met QC Criteria: March 27, 2014
• Last Verified: March 1, 2014

More Information

Terms related to this study

• Keywords: Glaucoma; intraocular pressure; retinal ganglion cell; latanoprost; pattern electroretinogram
• Additional Relevant MeSH Terms: Neoplasms; Eye Diseases; Cysts; Ocular Hypertension; Connective Tissue Diseases; Mucinoses; Glaucoma; Ganglion Cysts; Pharmaceutical Solutions; Ophthalmic Solutions; Latanoprost
• Other Study ID Numbers: 20057259